HC Wainwright & Co. Reiterates Buy on Viking Therapeutics, Maintains $33 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a 'Buy' rating on Viking Therapeutics (NASDAQ:VKTX) and maintained a price target of $33.
July 27, 2023 | 4:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Viking Therapeutics' stock is likely to be positively impacted by the reiterated 'Buy' rating and maintained price target of $33 by HC Wainwright & Co.
Analyst ratings and price targets can significantly influence the market perception of a stock. In this case, the 'Buy' rating and $33 price target by HC Wainwright & Co. indicates a positive outlook for Viking Therapeutics, which could lead to an increase in its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100